CEACAM-8 靶点蛋白|抗体药物|临床药物信息

CEACAM-8信息

英文名称：Non specific cross-reacting antigen 95
中文名称：非特异性交叉反应抗原95
靶点别称：Non-specific cross-reacting antigen NCA-95，CGM6，Carcinoembryonic Antigen Gene Family Member 6，CD66b Antigen，NCA-95，CD67，Carcinoembryonic antigen CGM6，CD66b，CEACAM8，Carcinoembryonic Antigen Related Cell Adhesion Molecule 8，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8，CD67 Antigen，CEA Cell Adhesion Molecule 8

上市药物数量：1
临床药物数量：1
最高研发阶段：批准上市

CEACAM-8产品列表

筛选结果

产品库

在线 (2)

物种

Human (2)

标签

属性

Protein (2)

标记

货号	物种	产品描述	蛋白结构	纯度	活性
CE8-H5224	Human	Human CEACAM-8 / CD66b Protein, His Tag
CE8-H82E9	Human	Biotinylated Human CEACAM-8 / CD66b Protein, His,Avitag™

CEACAM-8 分子别名

CEACAM8,CD66b,CD67,CGM6,NCA-95

CEACAM-8 分子背景

Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) is also known as CD66b (Cluster of Differentiation 66b), CD66b, CD67, CGM6, NCA-95, and is one of seven human CEACAM family members within the immunoglobulin superfamily. CEACAM family members are a set of widely expressed proteins involved in several biological functions, including cell adhesion, migration, signal transduction, and the regulation of gene expression. Abnormal overexpression and downregulation of some CEACAMs have been described in tumor cells. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM8 is a single chain, two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. It is an activation marker for human granulocytes.

CEACAM-8 前沿进展

CEACAM-8上市药物信息

英文名称	中文名称	研发代码	研发阶段	公司	最早商品名	最早批准国家	最早适应症	最早批准公司	最早批准日期	适应症	临床试验
Besilesomab		BW-250-183; 99Tcm-BW250-183; TLX-66-CDx; TLX66-CDx	批准上市	Cis Bio International Sa	Scintimun	EU	骨髓炎	Cis Bio International Sa	2010-01-11	骨髓炎	详情

CEACAM-8临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
90Y-DTPA-besilesomab	TLX-66	临床二期	Telix Pharmaceuticals Ltd	浆细胞瘤, 多发性骨髓瘤, 浆细胞肿瘤	详情

会议日历

会议一览

CEACAM-8